Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR And/or HER2 Mutations (SOLARA)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates BH-30643, an OMNI-EGFR inhibitor targeting mutant EGFR and HER2, in adults with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations, who have previously undergone standard therapies.

ClinicalTrials.gov ID: NCT06706076

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets patients with advanced solid tumors harboring mutations in the KRAS-MAPK pathway, including KRAS G12C, and involves treatment with MRTX0902, a selective SOS1 inhibitor that disrupts KRAS activation, either as monotherapy or in combination with the KRAS G12C inhibitor adagrasib. Eligible patients must have unresectable or metastatic disease and no curative treatment options, with an ECOG performance status of 0 or 1.

ClinicalTrials.gov ID: NCT05578092

KB707-02: a Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial investigates inhaled KB707, a modified HSV-1 vector delivering IL-12 and IL-2 to stimulate anti-tumor immune responses, in adults with advanced lung-affecting solid tumors, primarily NSCLC, particularly in combination with Keytruda and possibly chemotherapy. Participants are patients at stage 3 or 4 who have progressed on, are intolerant to, or refuse standard treatments.

ClinicalTrials.gov ID: NCT06228326

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients aged 18 and older with STK11-mutated advanced solid tumors, including subsets of NSCLC, and evaluates the safety and efficacy of the CoREST inhibitor TNG260 as a monotherapy and in combination with pembrolizumab. Participants must have adequate organ function and an ECOG status of 0 or 1.

ClinicalTrials.gov ID: NCT05887492

A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates MYTX-011, an antibody-drug conjugate targeting cMET, in patients with advanced, recurrent, or metastatic non-small cell lung cancer with cMET overexpression or MET structural variants, including those with EGFR mutations, who have progressed on standard therapies.

ClinicalTrials.gov ID: NCT05652868

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced, unresectable, or metastatic solid tumors with KRAS mutations, such as NSCLC, CRC, and PDAC, and evaluates the investigational panKRAS inhibitor PF-07934040, both alone and in combination with other treatments like chemotherapy and immunotherapy.

ClinicalTrials.gov ID: NCT06447662

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients with Advanced Non-small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastasized non-small cell lung cancer, focusing on those with unresectable disease post-chemoradiotherapy or refractory to PD-1/PD-L1 inhibitors, and evaluates the safety and efficacy of the investigational cancer vaccine BNT116, designed to elicit T-cell responses against six NSCLC antigens, administered alone and in combination with drugs including cemiplimab, docetaxel, or CTLA4 antibodies.

ClinicalTrials.gov ID: NCT05142189

A Phase 1b/2 Trial of Dupilumab Given in Conjunction with PD-1 or PD-L1 Blockade and Anakinra in the Treatment of Relapsed/refractory Metastatic NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the combination of Dupilumab, a monoclonal antibody targeting the IL-4 alpha receptor, with PD-1/PD-L1 blockade and Anakinra in adult patients with relapsed/refractory metastatic NSCLC who have progressed after prior PD-(L)1 therapies. Eligible patients must have an ECOG performance status of 0-2 and meet specific inclusion criteria, while those with certain uncontrolled illnesses or prior significant immunotherapy side effects are excluded.

ClinicalTrials.gov ID: NCT05013450

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.

ClinicalTrials.gov ID: NCT05227326

Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets adult patients with advanced solid tumors harboring the KRAS G12D mutation, focusing on those unresponsive to standard treatments, by investigating TSN1611, an oral agent designed to selectively inhibit both active and inactive forms of KRAS G12D.

ClinicalTrials.gov ID: NCT06385925